Jennifer Wichert

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Clinical Findings in Temporal Lobe Epilepsy Associated With Isolated Amygdala Enlargement.

Clinical Findings in Temporal Lobe Epilepsy Associated With Isolated Amygdala Enlargement.

Journal: European journal of neurology

Published: January 29, 2025

Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT.

Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT.

Journal: Cancers

Published: July 11, 2023

Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions.

Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions.

Journal: Cancers

Published: November 11, 2022

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.

Journal: Journal of neuro-oncology

Published: March 17, 2022

Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios

Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios

Journal: Nuklearmedizin. Nuclear medicine

Published: February 16, 2022

Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride.

Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride.

Journal: Cancers

Published: December 13, 2021

Local glucose metabolism is unaltered in reversible splenial lesion syndrome.

Local glucose metabolism is unaltered in reversible splenial lesion syndrome.

Journal: European journal of neurology

Published: October 26, 2021

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Journal: EJNMMI research

Published: April 23, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026